Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy
- PMID: 15117988
- DOI: 10.1200/JCO.2004.09.142
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy
Abstract
Purpose: Angiogenesis is a critical process for cancer progression. We tested whether elevated circulating levels of the angiogenesis-related markers vascular endothelial growth factor (VEGF) and/or soluble vascular cell adhesion molecule-1 (sVCAM-1) are associated with prostate cancer diagnosis, stage, progression, and metastasis.
Patients and methods: Plasma levels of VEGF and sVCAM-1 were measured on frozen, archival plasma obtained preoperatively from 215 consecutive patients who underwent radical prostatectomy for clinically localized disease, nine men with untreated prostate cancer metastatic to bones, and 40 healthy men without cancer.
Results: Plasma levels of both VEGF and sVCAM-1 were highest in patients with bone metastases (P <.001). VEGF levels were higher in patients with clinically localized disease than in healthy controls (P <.001). VEGF levels were elevated in patients with biopsy and final Gleason sum > or = 7 (P =.036 and P =.020, respectively) and extraprostatic extension (P =.047). Higher preoperative VEGF was independently associated with metastases to lymph nodes (P <.001). Both VEGF and sVCAM-1 were independently associated with biochemical progression after adjustment for the effects of standard preoperative features (P =.014 and P =.039, respectively). VEGF remained independently associated with biochemical progression after adjustment for standard postoperative features (P =.019).
Conclusion: Plasma levels of VEGF increased incrementally from healthy controls to patients with clinically localized disease to patients with lymph node and skeletal metastases. Higher preoperative VEGF was independently associated with metastases to lymph nodes and biochemical progression after surgery in both pre- and postoperative models. Plasma sVCAM-1 was elevated in men with bone metastases and was associated with biochemical progression in a preoperative model.
Similar articles
-
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.J Clin Oncol. 2007 Feb 1;25(4):349-55. doi: 10.1200/JCO.2006.05.6853. J Clin Oncol. 2007. PMID: 17264329
-
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.Cancer Res. 2002 Oct 15;62(20):5974-9. Cancer Res. 2002. PMID: 12384565
-
Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.J Urol. 2008 Apr;179(4):1593-7. doi: 10.1016/j.juro.2007.11.044. Epub 2008 Mar 4. J Urol. 2008. PMID: 18295256
-
Markers of angiogenesis and clinical features in patients with sarcoma.Cancer. 2007 Mar 1;109(5):813-9. doi: 10.1002/cncr.22455. Cancer. 2007. PMID: 17265525 Review.
-
The metastatic cascade in prostate cancer.Surg Oncol. 2006 Nov;15(3):117-28. doi: 10.1016/j.suronc.2006.10.002. Epub 2006 Dec 5. Surg Oncol. 2006. PMID: 17150354 Review.
Cited by
-
Association of the serum vascular endothelial growth factor levels with benign prostate hyperplasia and prostate malignancies.Nephrourol Mon. 2014 Apr 27;6(3):e14778. doi: 10.5812/numonthly.14778. eCollection 2014 May. Nephrourol Mon. 2014. PMID: 25032132 Free PMC article.
-
Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis.Int J Clin Exp Med. 2015 Feb 15;8(2):2289-98. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 25932165 Free PMC article.
-
Endocrine and paracrine characteristics of neuroendocrine prostate cancer.Front Endocrinol (Lausanne). 2022 Nov 11;13:1012005. doi: 10.3389/fendo.2022.1012005. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36440195 Free PMC article.
-
Positive family history as a predictor for disease outcomes after radical prostatectomy for nonmetastatic prostate cancer.Arab J Urol. 2023 Apr 3;21(4):241-247. doi: 10.1080/2090598X.2023.2196911. eCollection 2023. Arab J Urol. 2023. PMID: 38178943 Free PMC article.
-
Exercise-induced myokines and their effect on prostate cancer.Nat Rev Urol. 2021 Sep;18(9):519-542. doi: 10.1038/s41585-021-00476-y. Epub 2021 Jun 22. Nat Rev Urol. 2021. PMID: 34158658 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical